In conversation with...

Rosie Bradley on early-stage breast cancer treatment

February 28, 2022 The Lancet Oncology
In conversation with...
Rosie Bradley on early-stage breast cancer treatment
Show Notes

Rosie Bradley (Oxford Population Health, University of Oxford, Oxford, UK) discusses her Article on aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression.

Read the full article:
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression